STOCK TITAN

[Form 4] HEALTHEQUITY, INC. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

HealthEquity (HQY) reported an insider stock transaction. The company’s EVP and General Counsel sold 1,500 shares of common stock at $92.07 per share on 10/20/2025.

The sale was executed under a Rule 10b5-1 trading plan adopted on June 12, 2025. Following this transaction, the reporting person beneficially owns 76,979 shares, held directly.

HealthEquity (HQY) ha riportato una operazione azionaria da insider. Il vicepresidente esecutivo e avvocato generale della società ha venduto 1.500 azioni ordinarie a 92,07 dollari per azione il 20/10/2025. La vendita è stata eseguita nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 12 giugno 2025. Dopo questa operazione, la persona segnalante detiene beneficiariamente 76.979 azioni, direttamente.

HealthEquity (HQY) informó una operación de insider. El vicepresidente ejecutivo y asesor general de la empresa vendió 1.500 acciones ordinarias a 92,07 dólares por acción el 20/10/2025. La venta se ejecutó bajo un plan de negociación Rule 10b5-1 adoptado el 12 de junio de 2025. Tras esta operación, la persona reportante posee beneficiosamente 76.979 acciones, directamente.

HealthEquity (HQY)가 내부자 주식 거래를 보고했습니다. 회사의 EVP 겸 총괄고문이 보통주 1,500주를 주당 92.07달러에 매도했으며, 거래일은 2025-10-20입니다. 매매는 Rule 10b5-1 거래 계획에 따라 2025년 6월 12일에 채택된 계획 하에 실행되었습니다. 이 거래 이후 보고자는 76,979주를 직접 보유하고 있습니다.

HealthEquity (HQY) a déclaré une opération d'initié. Le vice-président exécutif et conseiller général de l'entreprise a vendu 1 500 actions ordinaires à 92,07 $ par action le 20/10/2025. La vente a été exécutée dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 12 juin 2025. Suite à cette opération, la personne déclarant détient 76 979 actions en direct.

HealthEquity (HQY) meldete eine Insider-Transaktion. Der EVP und General Counsel des Unternehmens verkaufte 1.500 Stammaktien zu 92,07 USD pro Aktie am 20.10.2025. Der Verkauf erfolgte im Rahmen eines Rule 10b5-1-Handelsplans, der am 12. Juni 2025 angenommen wurde. Nach dieser Transaktion besitzt die meldepflichtige Person direkt 76.979 Aktien.

HealthEquity (HQY) أبلغت عن صفقة أسهم داخلية. قام نائب الرئيس التنفيذي والمستشار العام للشركة ببيع 1,500 سهم من الأسهم العادية بسعر 92.07 دولارًا للسهم في 20/10/2025. تمت الصفقة وفق خطة تداول Rule 10b5-1 اعتمدت في 12 يونيو 2025. بعد هذه المعاملة، يمتلك الشخص المبلغ عنه مباشرةً 76,979 سهمًا من الأسهم.

HealthEquity (HQY) 报告了一笔内部人交易。公司执行副总裁兼总法律顾问以每股 92.07 美元 的价格出售了 1,500 股普通股,日期为 2025-10-20。此次出售是在于 2025 年 6 月 12 日通过的 Rule 10b5-1 交易计划 下执行的。交易完成后,报告人直接持有 76,979 股

Positive
  • None.
Negative
  • None.

HealthEquity (HQY) ha riportato una operazione azionaria da insider. Il vicepresidente esecutivo e avvocato generale della società ha venduto 1.500 azioni ordinarie a 92,07 dollari per azione il 20/10/2025. La vendita è stata eseguita nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 12 giugno 2025. Dopo questa operazione, la persona segnalante detiene beneficiariamente 76.979 azioni, direttamente.

HealthEquity (HQY) informó una operación de insider. El vicepresidente ejecutivo y asesor general de la empresa vendió 1.500 acciones ordinarias a 92,07 dólares por acción el 20/10/2025. La venta se ejecutó bajo un plan de negociación Rule 10b5-1 adoptado el 12 de junio de 2025. Tras esta operación, la persona reportante posee beneficiosamente 76.979 acciones, directamente.

HealthEquity (HQY)가 내부자 주식 거래를 보고했습니다. 회사의 EVP 겸 총괄고문이 보통주 1,500주를 주당 92.07달러에 매도했으며, 거래일은 2025-10-20입니다. 매매는 Rule 10b5-1 거래 계획에 따라 2025년 6월 12일에 채택된 계획 하에 실행되었습니다. 이 거래 이후 보고자는 76,979주를 직접 보유하고 있습니다.

HealthEquity (HQY) a déclaré une opération d'initié. Le vice-président exécutif et conseiller général de l'entreprise a vendu 1 500 actions ordinaires à 92,07 $ par action le 20/10/2025. La vente a été exécutée dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 12 juin 2025. Suite à cette opération, la personne déclarant détient 76 979 actions en direct.

HealthEquity (HQY) meldete eine Insider-Transaktion. Der EVP und General Counsel des Unternehmens verkaufte 1.500 Stammaktien zu 92,07 USD pro Aktie am 20.10.2025. Der Verkauf erfolgte im Rahmen eines Rule 10b5-1-Handelsplans, der am 12. Juni 2025 angenommen wurde. Nach dieser Transaktion besitzt die meldepflichtige Person direkt 76.979 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ladd Delano

(Last) (First) (Middle)
C/O HEALTHEQUITY, INC.
15 W. SCENIC POINTE DR., STE. 100

(Street)
DRAPER UT 84020

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY, INC. [ HQY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/20/2025 S(1) 1,500 D $92.07 76,979 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.
/s/ Delano Ladd 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did HQY disclose on Form 4?

An EVP and General Counsel sold 1,500 shares of HealthEquity common stock at $92.07 on 10/20/2025.

How many HQY shares does the insider own after the sale?

Post-transaction, the reporting person beneficially owns 76,979 shares, held directly.

Was the HQY insider sale under a Rule 10b5-1 plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2025.

Who is the HQY insider involved in the Form 4?

An Officer of HealthEquity serving as EVP, General Counsel.

What was the transaction code reported?

The filing lists transaction code S, indicating a sale.

What is the ownership form of the reported HQY holdings?

The holdings are reported as Direct (D) ownership.
Healthequity Inc

NASDAQ:HQY

HQY Rankings

HQY Latest News

HQY Latest SEC Filings

HQY Stock Data

8.27B
84.32M
2.21%
108.47%
5.82%
Health Information Services
Services-business Services, Nec
Link
United States
DRAPER